O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158

Shunji Takahashi,Nobumasa Mizuno,Kosei Hasegawa,Koji Matsumoto,Shirong Han,Tsutomu Takatsuki,Fan Jin,Kazuhiko Nakagawa

doi:10.1016/j.annonc.2022.05.059

O19-4 Outcomes in Japanese patients with TMB-high and non-TMB-high solid tumors treated with pembrolizumab: KEYNOTE-158

Shunji Takahashi, Nobumasa Mizuno + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2022.05.059

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2022
License type: publisher-specific-oa

Affiliation: Japanese Foundation For Cancer Research, Aichi Cancer Center, Saitama Medical University, Kindai University Hospital

#Tissue Tumor Mutational Burden #Outcomes In Japanese Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tissue tumor mutational burden (tTMB) was correlated with response to pembrolizumab (pembro) monotherapy in the global phase 2 KEYNOTE-158 study (NCT02628067). We report an analysis of the relationship between the response to pembro and tTMB in patients with advanced solid tumors in the KEYNOTE-158 study enrolled in Japan.

Full Text